FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945441876> ?p ?o ?g. }

• W2945441876 endingPage "iii4" @default.
• W2945441876 startingPage "iii4" @default.
• W2945441876 abstract "Background: TNBC represents an unmet clinical need; the IMPassion 130 and KEYNOTE-086 trials have demonstrated efficacy of PD-1/PD-L1 targeted therapeutics in the metastatic/unresectable first line setting, with increased response in PD-L1 high populations, defined using different diagnostic assays and algorithms. This work addresses the need to establish PD-L1 assay concordance in TNBC. Methods: 196 TNBC cases were stained by IHC using the VENTANA PD-L1 (SP263), VENTANA PD-L1 (SP142), Dako PD-L1 IHC 28-8 pharmDx and Dako PD-L1 IHC 22C3 pharmDx assays. A single pathologist scored the proportions of membrane staining tumour cells (TC), staining immune cells (IC) and tumour occupied by immune cells. The proportion of tumour occupied by staining immune cells (ICTA) and Combined Positive Score (CPS) were derived. Concordance between assays was evaluated using the Spearman coefficient ρ. Concordance in patient status was assessed using overall, positive and negative percent agreement (OPA/PPA/NPA) at matched algorithms and cut-offs. Results: SP263, 22C3 and 28-8 assays showed good analytical correlation for TC staining (ρ = 0.84–0.89), but lower for SP142 (0.44-0.46), whereas all assays showed good correlation for ICTA (0.77-0.96) and CPS (0.78-0.95). OPA ranged from 58%–97% at matched algorithms (Table). Prevalence for SP142 ICTA≥1% and 22C3 CPS≥1 was in-line with IMPassion 130 and KEYNOTE-086, respectively. Conclusions: Analytical performance between SP263, 22C3 and 28-8 is very similar; SP142 stains fewer TCs and ICs. In contrast to other cancer types, in TNBC, TC scores are lower and IC scores are higher. Care should be taken when interchanging PD-L1 assays and interpreting efficacy data derived with different algorithms in TNBC; whilst SP263 would identify largely the same PD-L1 patient population as on KEYNOTE-086, it could potentially identify 22% additional cases as PD-L1 high than on IMPassion 130. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: M. Scott, P. Scorer, C. Barker: Employee, shareholder: AstraZeneca. H. Al-Masri: Employee: Hematogenix. Table10O Prevalence (%) and OPA (%) of VENTANA SP263 with other assays at matched cut-offsSP26322C322C328-828-8SP142SP142Cut-offPrevalencePrevalenceOPAPrevalenceOPAPrevalenceOPATC ≥ 1%53509146881158ICTA≥1%54519652973278CPS≥164609261953571 Open table in a new tab" @default.
• W2945441876 created "2019-05-29" @default.
• W2945441876 creator A5000175781 @default.
• W2945441876 creator A5059929544 @default.
• W2945441876 creator A5069957752 @default.
• W2945441876 creator A5087350151 @default.
• W2945441876 date "2019-05-01" @default.
• W2945441876 modified "2023-10-16" @default.
• W2945441876 title "Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)" @default.
• W2945441876 doi "https://doi.org/10.1093/annonc/mdz095.009" @default.
• W2945441876 hasPublicationYear "2019" @default.
• W2945441876 type Work @default.
• W2945441876 sameAs 2945441876 @default.
• W2945441876 citedByCount "24" @default.
• W2945441876 countsByYear W29454418762019 @default.
• W2945441876 countsByYear W29454418762020 @default.
• W2945441876 countsByYear W29454418762021 @default.
• W2945441876 countsByYear W29454418762022 @default.
• W2945441876 countsByYear W29454418762023 @default.
• W2945441876 crossrefType "journal-article" @default.
• W2945441876 hasAuthorship W2945441876A5000175781 @default.
• W2945441876 hasAuthorship W2945441876A5059929544 @default.
• W2945441876 hasAuthorship W2945441876A5069957752 @default.
• W2945441876 hasAuthorship W2945441876A5087350151 @default.
• W2945441876 hasBestOaLocation W29454418761 @default.
• W2945441876 hasConcept C121608353 @default.
• W2945441876 hasConcept C126322002 @default.
• W2945441876 hasConcept C142724271 @default.
• W2945441876 hasConcept C143998085 @default.
• W2945441876 hasConcept C160798450 @default.
• W2945441876 hasConcept C204232928 @default.
• W2945441876 hasConcept C2777701055 @default.
• W2945441876 hasConcept C2780416959 @default.
• W2945441876 hasConcept C2781053074 @default.
• W2945441876 hasConcept C71924100 @default.
• W2945441876 hasConcept C74864618 @default.
• W2945441876 hasConceptScore W2945441876C121608353 @default.
• W2945441876 hasConceptScore W2945441876C126322002 @default.
• W2945441876 hasConceptScore W2945441876C142724271 @default.
• W2945441876 hasConceptScore W2945441876C143998085 @default.
• W2945441876 hasConceptScore W2945441876C160798450 @default.
• W2945441876 hasConceptScore W2945441876C204232928 @default.
• W2945441876 hasConceptScore W2945441876C2777701055 @default.
• W2945441876 hasConceptScore W2945441876C2780416959 @default.
• W2945441876 hasConceptScore W2945441876C2781053074 @default.
• W2945441876 hasConceptScore W2945441876C71924100 @default.
• W2945441876 hasConceptScore W2945441876C74864618 @default.
• W2945441876 hasLocation W29454418761 @default.
• W2945441876 hasOpenAccess W2945441876 @default.
• W2945441876 hasPrimaryLocation W29454418761 @default.
• W2945441876 hasRelatedWork W1514899824 @default.
• W2945441876 hasRelatedWork W1992481203 @default.
• W2945441876 hasRelatedWork W1993946980 @default.
• W2945441876 hasRelatedWork W2013745628 @default.
• W2945441876 hasRelatedWork W2035464821 @default.
• W2945441876 hasRelatedWork W2040976599 @default.
• W2945441876 hasRelatedWork W2232352716 @default.
• W2945441876 hasRelatedWork W2429210815 @default.
• W2945441876 hasRelatedWork W2767901395 @default.
• W2945441876 hasRelatedWork W50742768 @default.
• W2945441876 hasVolume "30" @default.
• W2945441876 isParatext "false" @default.
• W2945441876 isRetracted "false" @default.
• W2945441876 magId "2945441876" @default.
• W2945441876 workType "article" @default.